Although the safety and efficacy of combining CEP-1347 with RG7112 or other MDM2 inhibitors need to be investigated in future preclinical and clinical studies, our in vitro results suggest that this combination represents a feasible and effective approach in the treatment of malignant brain tumors with wild-type p53. Here, TP53 is linked to brain cancer.